Atlas company financials

Apellis Pharmaceuticals, Inc.

Standardized 6-year financial series for Apellis Pharmaceuticals, Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001492422FY2020 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$1B

Adjusted EBITDA

—

Net result

$22.4M

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$458.6M

TTM revenue

$1B

TTM free cash flow

—

Latest quarter net result

$215.7M

Quarterly coverage: 16 periods · latest quarter FY2025-Q3 · TTM revenue growth 73.3%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · apellis-pharmaceuticals-inc-fy2020 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2021-02-25 · Retrieved: 2026-04-26T11:53:49.137321+00:00
SEC EDGAR companyfacts
us-gaap:EarningsPerShareBasic · us gaap companyfacts · comparative · apellis-pharmaceuticals-inc-fy2020 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2023-02-21 · Retrieved: 2026-04-26T11:53:49.137321+00:00
SEC EDGAR companyfacts
us-gaap:InventoryNet · us gaap companyfacts · comparative · apellis-pharmaceuticals-inc-fy2020 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2022-02-28 · Retrieved: 2026-04-26T11:53:49.137321+00:00
SEC EDGAR companyfacts
us-gaap:SellingGeneralAndAdministrativeExpense · us gaap companyfacts · comparative · apellis-pharmaceuticals-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2025-02-28 · Retrieved: 2026-04-26T11:53:49.137321+00:00
SEC EDGAR companyfacts
primary · apellis-pharmaceuticals-inc-fy2023 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2024-02-29 · Retrieved: 2026-04-26T11:53:49.137321+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2020	251M	—	-214M	-345M	-160M	-5M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt · missing sg and a
FY2021	67M	—	-536M	-746M	-563M	-1M	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt · missing sg and a
FY2022	75M	—	-595M	-652M	-514M	-2M	-459M	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense
FY2023	397M	—	-517M	-529M	-595M	-773K	-258M	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense
FY2024	781M	—	-165M	-198M	-88M	-403K	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt
FY2025	1B	—	55M	22M	45M	-313K	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt

Filing provenance